<DOC>
	<DOCNO>NCT00900224</DOCNO>
	<brief_summary>RATIONALE : Studying sample tissue blood patient cancer laboratory may help doctor learn change occur DNA identify biomarkers related cancer . PURPOSE : This research study look tissue blood sample patient acute myeloid leukemia .</brief_summary>
	<brief_title>Studying Tissue Blood Samples From Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Prospectively obtain specimen require diagnostic review molecular characterization ensure eligibility CALGB Leukemia Committee Clinical trial ( clinical trial design enroll specific molecular subtypes , result determine eligibility report treating physician 72 hour specimen receipt repository ) . - Determine frequency specific gene marker ( i.e. , FLT3 ITD , CBF , MLL PTD , NPM1 , KIT , RAS , CEBPA , WT1 , JAK2 , RUNX1 , TET2 , CBL , IDH1 IDH2 , ASXL1 , mutation , aberrant BAALC , ERG , FLT3 , MN1 , EVI1 , APP ) over-expression level promoter methylation specific gene ( e.g. , ESR1 , WIT1 , P15 , MYOD1 , ID4 , DPK ) define cytogenetic subgroup patient acute myeloid leukemia ( AML ) . - Correlate gene marker clinical laboratory parameter patient . - Correlate gene marker clinical outcome ( i.e. , complete remission [ CR ] , disease-free survival [ DFS ] , cumulative incidence relapse [ CIR ] , overall survival [ OS ] ) patient . - Identify specific microarray multi-gene expression signatures patient . - Correlate specific microarray multi-gene expression signatures clinical laboratory parameter patient . - Correlate specific microarray multi-gene expression signatures clinical outcome ( i.e. , CR , DFS , CIR , OS ) patient . - Identify specific microarray multi-microRNA ( miR ) expression signatures patient - Correlate specific microarray multi-miR expression signatures clinical laboratory parameter patient . - Correlate specific microarray multi-miR expression signatures clinical outcome ( i.e. , CR , DFS , CIR , OS ) patient . - Explore relative contribution prognostic gene marker ( i.e. , FLT3 ITD , MLL PTD , NPM1 , KIT , RAS , CEBPA , WT1 , JAK2 mutation , aberrant BAALC , ERG , FLT3 , MN1 , EVI1 over-expression ) , level promoter methylation specific gene ( e.g. , ESR1 , WIT1 , P15 , MYOD1 , ID4 , DPK ) , microarray gene miR expression signature define cytogenetic subgroup AML . - Determine change molecular marker microarray gene miR expression signature CR relapse influence change subsequent clinical course . - Correlate relative level nuclear pSTAT5 pERK bone marrow blast outcome ( EFS , CR , DFS , OS ) . OUTLINE : This multicenter study . Previously procure archive bone marrow aspirate sample , blood buccal cell sample , bone marrow biopsy slide analyze FLT3 ITD , MLL PTD , NPM1 , KIT , KRAS , NRAS , CEBPA , WT1 , JAK2 , RUNX1 , TET2 , ASXL1 , IDH1 IDH2 , CBL mutation , CBF fusion gene , level BAALC , ERG , EVI1 , MN1 , APP microarray gene-expression , microRNA gene-expression signature , level methylation gene silence AML , genomic DNA PCR amplification , RT-PCR , denature high-performance liquid chromatography .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm acute myeloid leukemia ( AML ) Tissue sample previously untreated patient AML consider enrollment onto ongoing future CALGB treatment protocol AML tissue sample companion Leukemia Tissue Bank protocol CALGB9665 companion cytogenetic protocol CALGB8461 AML diagnostic bone marrow and/or blood sample patient enrol CLB9720 , CLB9621 ( cytogenetic subtypes ) , CALGB19808 ( abnormal cytogenetics )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>untreated childhood acute myeloid leukemia myeloid malignancy</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
</DOC>